241 related articles for article (PubMed ID: 23916904)
1. The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload.
Sivgin S; Baldane S; Akyol G; Keklik M; Kaynar L; Kurnaz F; Pala C; Zararsiz G; Cetin M; Eser B; Unal A
Transfus Apher Sci; 2013 Oct; 49(2):295-301. PubMed ID: 23916904
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT).
Sivgin S; Eser B; Bahcebasi S; Kaynar L; Kurnaz F; Uzer E; Pala C; Deniz K; Ozturk A; Cetin M; Unal A
Ann Hematol; 2012 May; 91(5):743-749. PubMed ID: 22051904
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
[TBL] [Abstract][Full Text] [Related]
4. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
Chang HH; Lu MY; Liao YM; Lin PC; Yang YL; Lin DT; Chiou SS; Jou ST; Lin KH; Chang TT
Pediatr Blood Cancer; 2011 Mar; 56(3):420-4. PubMed ID: 21072825
[TBL] [Abstract][Full Text] [Related]
5. Increased Hepatic Iron Content Predicts Poor Survival in Patients With Iron Overload Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation.
Sivgin S; Baldane S; Deniz K; Zararsiz G; Kaynar L; Cetin M; Unal A; Eser B
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S10-8. PubMed ID: 27521305
[TBL] [Abstract][Full Text] [Related]
6. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
7. Restoration of hematopoiesis after iron chelation therapy with deferasirox in 2 children with severe aplastic anemia.
Koh KN; Park M; Kim BE; Im HJ; Seo JJ
J Pediatr Hematol Oncol; 2010 Nov; 32(8):611-4. PubMed ID: 20881872
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
Chen CH; Shu KH; Yang Y
Hematology; 2015 Jun; 20(5):304-10. PubMed ID: 25200910
[TBL] [Abstract][Full Text] [Related]
9. Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302).
Tachibana T; Kanda J; Machida S; Saito T; Tanaka M; Najima Y; Koyama S; Miyazaki T; Yamamoto E; Takeuchi M; Morita S; Kanda Y; Kanamori H; Okamoto S;
Int J Hematol; 2018 May; 107(5):578-585. PubMed ID: 29305770
[TBL] [Abstract][Full Text] [Related]
10. Deferasirox therapy in children with Fanconi aplastic anemia.
Tunç B; Tavil B; Karakurt N; Yarali N; Azik FM; Kara A; Culha V; Ozkasap S
J Pediatr Hematol Oncol; 2012 May; 34(4):247-51. PubMed ID: 22510772
[TBL] [Abstract][Full Text] [Related]
11. Iranian experience of deferasirox (Exjade(®)) in transfusion-dependent patients with iron overload: what is the most effective dose based on serum ferritin levels?
Karimi M; Azarkeivan A; Zareifar S; Cohan N; Bordbar MR; Haghpanah S
Hematology; 2012 Nov; 17(6):367-71. PubMed ID: 23168076
[TBL] [Abstract][Full Text] [Related]
12. Impact of Iron Overload and Iron Chelation with Deferasirox on Outcomes of Patients with Severe Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation.
Pan T; Ji Y; Liu H; Tang B; Song K; Wan X; Yao W; Sun G; Wang J; Sun Z
Transplant Cell Ther; 2023 Aug; 29(8):507.e1-507.e8. PubMed ID: 37116582
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.
Kim IH; Moon JH; Lim SN; Sohn SK; Kim HG; Lee GW; Kim YS; Lee HS; Kwon KY; Kim SH; Park KT; Chung JS; Lee WS; Lee SM; Hyun MS; Kim H; Ryoo HM; Bae SH; Joo YD
Transfusion; 2015 Jul; 55(7):1613-20. PubMed ID: 25764017
[TBL] [Abstract][Full Text] [Related]
14. Effect of deferasirox on iron overload in patients with transfusion-dependent haemoglobinopathies.
Fragomeno C; Roccabruna E; D'Ascola DG
Blood Cells Mol Dis; 2015 Dec; 55(4):382-6. PubMed ID: 26460263
[TBL] [Abstract][Full Text] [Related]
15. A prospective phase II randomized study of deferasirox to prevent iatrogenic iron overload in patients undertaking induction/consolidation chemotherapy for acute myeloid leukaemia.
Kennedy GA; Morris KL; Subramonpillai E; Curley C; Butler J; Durrant S
Br J Haematol; 2013 Jun; 161(6):794-801. PubMed ID: 23590671
[TBL] [Abstract][Full Text] [Related]
16. A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors.
Majhail NS; Lazarus HM; Burns LJ
Biol Blood Marrow Transplant; 2010 Jun; 16(6):832-7. PubMed ID: 20079863
[TBL] [Abstract][Full Text] [Related]
17. Posttransplant oral iron-chelating therapy in patients with beta-thalassemia major.
Yesilipek MA; Karasu G; Kazik M; Uygun V; Ozturk Z
Pediatr Hematol Oncol; 2010 Aug; 27(5):374-9. PubMed ID: 20604682
[TBL] [Abstract][Full Text] [Related]
18. The impact of pretransplant hypoalbuminemia on survival in patients with leukemia who underwent allogeneic hematopoietic stem cell transplantation (alloHSCT): a nutritional problem?
Sivgin S; Baldane S; Ozenmis T; Keklik M; Kaynar L; Kurnaz F; Sivgin H; Zararsız G; Cetin M; Unal A; Eser B
Transplant Proc; 2013 Nov; 45(9):3371-4. PubMed ID: 24182818
[TBL] [Abstract][Full Text] [Related]
19. Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil.
Al-Rousan RM; Paturi S; Laurino JP; Kakarla SK; Gutta AK; Walker EM; Blough ER
Am J Hematol; 2009 Sep; 84(9):565-70. PubMed ID: 19650117
[TBL] [Abstract][Full Text] [Related]
20. Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.
Escudero-Vilaplana V; Garcia-Gonzalez X; Osorio-Prendes S; Romero-Jimenez RM; Sanjurjo-Saez M
J Clin Pharm Ther; 2016 Feb; 41(1):59-63. PubMed ID: 26778738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
